Therapeutic applications of octreotide in pediatric patients
Open Access
- 1 January 2012
- journal article
- research article
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 18 (2) , 87-94
Abstract
Background/Aim: We report our experience with the use of octreotide as primary or adjunctive therapy in children with various gastrointestinal disorders. Patients and Methods: A pharmacy database identified patients who received octreotide for gastrointestinal diseases. Indications for octreotide use, dosing, effectiveness, and adverse events were evaluated by chart review. Results: A total of 21 patients (12 males), aged 1 month to 13 years, were evaluated. Eleven received octreotide for massive gastrointestinal bleeding caused by portal hypertension-induced lesions (n=7), typhlitis (1), Meckel's diverticulum (1), and indefinite source (2). Blood transfusion requirements were reduced from 23±9 mL/kg (mean±SD) to 8±15 mL/kg (P<0.01). Four patients with pancreatic pseudocyst and/or ascites received octreotide over 14.0±5.7 days in 2 patients. In 3 children, pancreatic pseudocyst resolved in 12±2 days and pancreatic ascites resolved in 7 days in 2. Three patients with chylothorax received octreotide for 14±7 days with complete resolution in each. Two infants with chronic diarrhea received octreotide over 11±4.2 months. Stool output decreased from 85±21 mL/kg/day to 28±18 mL/kg/day, 3 months after initiation of octreotide. The child with dumping syndrome responded to octreotide in a week. Adverse events developed in 4 patients: Q-T interval prolongation and ventricular fibrillation, hyperglycemia, growth hormone deficiency, and hypertension. Conclusion: Octreotide provides a valuable addition to the therapeutic armamentum of the pediatric gastroenterologist for a wide variety of disorders. Serious adverse events may occur and patients must be closely monitored.Keywords
This publication has 66 references indexed in Scilit:
- Etiology and management of pediatric chylothoraxThe Journal of Pediatrics, 2000
- Clinical use of the long acting somatostatin analogue octreotide in pediatricsEuropean Journal of Pediatrics, 1994
- Pharmacodynamic Effects of Sandostatin® in the Gastrointestinal TractDigestion, 1993
- A randomized controlled trial comparing octreotide and vasopressin in the control of acute esophageal variceal bleedingJournal of Hepatology, 1992
- Adverse Effect of Therapeutic Vasoconstrictors in Experimental Acute PancreatitisAnnals of Surgery, 1991
- Linear growth during long-term treatment with somatostatin analog (SMS 201-995) for persistent hyperinsulinemic hypoglycemia of infancyThe Journal of Pediatrics, 1990
- PERSISTENT HYPERINSULINAEMIC HYPOGLYCAEMIA OF INFANCY: LONG‐TERM TREATMENT WITH THE SOMATOSTATIN ANALOGUE SANDOSTATIN†Clinical Endocrinology, 1989
- Effect of somatostatin 14 on pure human pancreatic secretionDigestive Diseases and Sciences, 1987
- Effect of the Somatostatin Analogue Sandostatin (SMS 201–995) on Gastrointestinal, Pancreatic and Biliary Function and Hormone Release in Normal MenDigestion, 1987
- Effect of long acting somatostatin-analogue, SMS 201995, on gut hormone secretion in normal subjectsCellular and Molecular Life Sciences, 1985